uploads///Baraclude

How BMY’s Baraclude and Sustiva Franchise Performed

By

Mar. 7 2018, Updated 10:31 a.m. ET

Baraclude revenue trends

In 4Q17, Bristol-Myers Squibb’s (BMY) Baraclude generated revenues of $233 million, a ~21% decline on a year-over-year (or YoY) basis and a ~12% decline on a quarter-over-quarter basis. In 4Q17, Baraclude witnessed a ~24% and ~21% decline on a YoY basis in the US market and international markets, respectively. In fiscal 2017, Baraclude generated revenues of $1.1 billion, a ~12% decline on a YoY basis. 

Article continues below advertisement

In 2017, in the US market and international markets, Baraclude reported revenues of $53 million and $999 million, respectively, compared to $66 million and $1.1 billion in 2016. In the hepatitis B virus drugs market, Baraclude competes with Epivir, an anti-HBV drug from Pfizer (PFE) and GlaxoSmithKline’s (GSK) joint venture with ViiV Healthcare and Gilead Sciences’ Viread.

Sustiva franchise revenue trends

In 4Q17, the Sustiva franchise reported revenues of $174 million, which reflected a ~29% decline on a YoY basis and a ~5% decline on a quarter-over-quarter basis. In 4Q17, in the US market and international markets, the Sustiva franchise generated revenues of $151 million and $23 million, respectively, compared to $212 million and $34 million in 4Q16.

In 4Q17, in the US market and international markets, the Sustiva franchise witnessed a ~29% and ~32% decline on a YoY basis. In fiscal 2017, the Sustiva franchise reported revenues of $729 million, which reflected a ~32% decline on a YoY basis.

In 2017, in the US market and international markets, the Sustiva franchise generated revenues of $622 million and $107 million, respectively, compared to $901 million and $164 million in 2016.

In the anti-HIV-1 (human immunodeficiency virus type 1) infection drugs market, Bristol-Myers Squibb’s Sustiva franchise faced stiff competition from Gilead Sciences’ (GILD) Atripla and Johnson & Johnson’s (JNJ) Edurant.

Advertisement

More From Market Realist